The U.S. Food and Drug Administration (FDA) has approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy, to improve chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), according to official records.
This approval marks a significant advancement in treating a complication that affects many patients receiving donor stem cells. TREGZI uses specialized immune cells to modulate the body’s response to transplanted cells, reducing the risk of GVHD while preserving the graft-versus-cancer effect.
The FDA’s decision follows a review of clinical trial data demonstrating a reduction in chronic GVHD cases compared to standard care. The agency granted the therapy Breakthrough Therapy designation, recognizing its potential to address a critical unmet need in oncology.
What is TREGZI and How Does It Work?
TREGZI is a cell-based therapy that isolates and expands regulatory T cells (Tregs) from donor blood samples. These cells are engineered to suppress overactive immune responses while maintaining the ability to fight cancer. The process involves culturing the cells in specialized bioreactors before reinfusing them into patients, typically within 72 hours of stem cell transplantation.
Chronic GVHD occurs when donor immune cells attack the recipient’s healthy tissues, often affecting the skin, liver, and lungs. It is a leading cause of long-term morbidity and mortality after allo-HSCT, with some patients developing severe forms of the condition.
Why This Approval Is Significant
This is the first FDA-approved therapy specifically targeting the prevention of chronic GVHD through immune modulation rather than broad immunosuppression. Traditional treatments, such as corticosteroids, carry risks of infections and organ toxicity, while TREGZI’s mechanism aims to address the root cause of the immune dysregulation.
What the Clinical Trials Showed
The FDA’s approval was based on data from a pivotal Phase 3 trial involving 212 patients across 25 U.S. medical centers. The study found that a majority of TREGZI-treated patients remained free from chronic GVHD at 12 months, compared to those in the control group. The therapy also reduced the incidence of severe GVHD, with no significant increase in infections or cancer relapse rates.
Adverse events were generally mild, with some patients experiencing transient flu-like symptoms. The most common side effect was transient lymphopenia, which resolved without intervention in all cases.
How This Impacts Blood Cancer Treatment
The approval is expected to change standards of care for patients undergoing allo-HSCT, particularly those with high-risk features such as mismatched donors or prior GVHD. The therapy is currently available at 12 specialized centers.
What Comes Next?
The FDA has set a follow-up meeting to review long-term safety data, as part of its Risk Evaluation and Mitigation Strategy (REMS) requirements. Meanwhile, additional studies are being conducted to evaluate TREGZI’s effectiveness in pediatric patients and those with rare blood cancers.
Healthcare providers are being trained on the therapy’s administration protocols. The cost of treatment is estimated at a significant amount per patient, though insurance coverage is being negotiated with major payers.
What Patients Should Know
Patients considering TREGZI should consult their transplant team to determine eligibility. The therapy is not approved for use in patients with active infections or certain types of cancer that may progress during treatment. Side effects are typically managed with supportive care, and patients are monitored closely for 30 days post-infusion.
Expert Reactions
The approval has been widely praised by the medical community.
However, some experts caution that long-term data is still limited. “We need to see